Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Long-Term Debt Repayments (2017 - 2025)

Cumberland Pharmaceuticals' Long-Term Debt Repayments history spans 11 years, with the latest figure at $10.0 million for Q1 2025.

  • For Q1 2025, Long-Term Debt Repayments rose 30.33% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, down 72.12%, while the annual FY2025 figure was $10.0 million, 72.12% down from the prior year.
  • Long-Term Debt Repayments for Q1 2025 was $10.0 million at Cumberland Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $20.0 million in Q2 2022 and bottomed at $6.3 million in Q4 2024.
  • The 5-year median for Long-Term Debt Repayments is $11.0 million (2024), against an average of $11.8 million.
  • The largest annual shift saw Long-Term Debt Repayments skyrocketed 76.47% in 2021 before it plummeted 45.82% in 2023.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $14.0 million in 2021, then crashed by 45.0% to $7.7 million in 2022, then rose by 5.55% to $8.1 million in 2023, then dropped by 22.3% to $6.3 million in 2024, then skyrocketed by 58.9% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Long-Term Debt Repayments are $10.0 million (Q1 2025), $6.3 million (Q4 2024), and $11.0 million (Q3 2024).